US Enhanced Surveillance Network to Assess Burden, Natural History, and Effectiveness of Vaccines to Prevent Enteric and Respiratory Viruses in Children

US Enhanced Surveillance Network to Assess Burden, Natural History, and Effectiveness of Vaccines to Prevent Enteric and Respiratory Viruses in Children is sponsored by Centers for Disease Control and Prevention (CDC). This opportunity supports mission-aligned projects and measurable outcomes.

A **. gov** website belongs to an official government organization in the United States.

* How to Apply for Grants * **Applicant Resources** * Adobe Software Compatibility * Submitting UTF-8 Special Characters * Encountering Error Messages * Grantor Standard Language * Submitting UTF-8 Special Characters * **Applicant System-To-System** * Reference Implementation * **Grantor System-To-System** * Reference Implementation * SF-424 Individual Family * SF-424 Mandatory Family * SF-424 Short Organization Family * Post-Award Reporting Forms * Country and State Lists Updates * **Manage Subscriptions** * Program Management Office * Grants.

gov Maintenance Calendar US Enhanced Surveillance Network to Assess Burden, Natural History, and Effectiveness of Vaccines to Prevent Enteric and Respiratory Viruses in Children Department of Health and Human Services Centers for Disease Control and Prevention - ERA Document Type:Grants Notice Funding Opportunity Number:RFA-IP-21-002 Funding Opportunity Title:US Enhanced Surveillance Network to Assess Burden, Natural History, and Effectiveness of Vaccines to Prevent Enteric and Respiratory Viruses in Children Opportunity Category:Discretionary Opportunity Category Explanation: Funding Instrument Type:Cooperative Agreement Category of Funding Activity:Health Expected Number of Awards:7 Assistance Listings:93.

185 -- Immunization Research, Demonstration, Public Information and Education Training and Clinical Skills Improvement Projects Cost Sharing or Matching Requirement:No Last Updated Date:Mar 03, 2021 Original Closing Date for Applications:Feb 08, 2021 Electronically submitted applications must be submitted no later than 5:00 p. m. , ET, on the listed application due date.

Current Closing Date for Applications:Mar 08, 2021 Electronically submitted applications must be submitted no later than 5:00 p. m. , ET, on the listed application due date.

Archive Date:Mar 10, 2021 Estimated Total Program Funding:$ 68,250,000 Eligible Applicants:City or township governments Nonprofits having a 501(c)(3) status with the IRS, other than institutions of higher education Independent school districts Public housing authorities/Indian housing authorities Special district governments Public and State controlled institutions of higher education Others (see text field entitled "Additional Information on Eligibility" for clarification) Native American tribal governments (Federally recognized) Nonprofits that do not have a 501(c)(3) status with the IRS, other than institutions of higher education Native American tribal organizations (other than Federally recognized tribal governments) Additional Information on Eligibility:Public and private non-profit institutions of higher educationThe following types of Higher Education Institutions are always encouraged to apply for CDC support as Public or Private Nonprofit Institutions of Higher Education:Hispanic-serving InstitutionsHistorically Black Colleges and Universities (HBCUs)Tribally Controlled Colleges and Universities (TCCUs)Alaska Native and Native Hawaiian Serving Institutions ## Additional Information Agency Name:Centers for Disease Control and Prevention - ERA Description:The goal of this Notice of Funding Opportunity (NOFO) is to support a network of US institutions to develop and implement standard research protocols to conduct prospective active surveillance for: a) acute gastroenteritis (AGE) due to norovirus, rotavirus and other enteric viruses; b) acute respiratory illnesses (ARI) due to respiratory viruses including, but not limited to, influenza, RSV, parainfluenza viruses, human metapneumovirus, rhinoviruses, enteroviruses (including EV-D68), adenoviruses, and coronaviruses (including SARS-CoV-2); and c) acute flaccid myelitis (AFM) syndrome and multisystem inflammatory syndrome in children (MIS-C) among pediatric patients seeking healthcare at medical institutions.

The network should also provide accurate estimates of the effectiveness in this population of influenza, rotavirus, COVID-19 and other vaccines against respiratory or enteric virus-associated illnesses projected to become available during the period of performance (e.g., RSV, norovirus).

Participating institutions should identify AGE, ARI, AFM and MIS-C illnesses among pediatric patients seeking healthcare or diagnostic testing for acute illness in inpatient, outpatient and emergency departments. Recipients should enroll patients meeting standard symptom criteria, and confirm viral infection using approved molecular assays. Vaccine effectiveness (VE) estimates will be calculated.

Estimates of VE, burden of disease, and information on the natural history of disease will be used to: a) inform best practices for diagnosis and treatment protocols; b) inform vaccine recommendations; and c) assess public health impact of vaccination and public health programs to prevent viral illness-related healthcare encounters and medical visits among pediatric populations. Link to Additional Information:[](https://www. grants.

gov/search-results-detail/328354) Grantor Contact Information:If you have difficulty accessing the full announcement electronically, please contact: #### Health & Human Services * Frequently Asked Questions ## Your session will expire in 3 minutes. To continue working, click on the "OK" button below. This is being done to protect your privacy.

Unsaved changes will be lost.